99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study
to investigate the imaging performance of 99mTc-MIRC213 in breast cancer patients. A single
dose of 11.1-14.8Mega-Becquerel (MBq) per kilogram body weight 99mTc-MIRC213 will be injected
intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.